Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: A post-study survey

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 3, 2010, Pages 269-277

  Schuetz, P ^a,b   Batschwaroff, M ^b   Dusemund, F ^b   Albrich, W ^b   Burgi U ^b   Maurer, M ^b   Brutsche, M ^b   Huber, A R ^c   Muller B ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Aarau   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN;

ADULT; AGED; ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MISUSE; DRUG RESPONSE; FEMALE; HEALTH SURVEY; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; RESPIRATORY TRACT INFECTION; RISK REDUCTION; SWITZERLAND; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-BACTERIAL AGENTS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RESPIRATORY TRACT INFECTIONS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77952426755     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-009-0851-0     Document Type: Article

References (17)

1. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131(1):9-19
2. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B (2007) Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 7:102
3. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B (2006) Procalcitonin guidance of antibiotic therapy in communityacquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174(1):84-93
4. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B (2004) Effect of procalcitoninguided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409):600-607
5. BrielM, Schuetz P,Müller B, Young J, Schild U, Nusbaumer C, Périat P, Bucher HC, Christ-CrainM(2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000-2007
6. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177(5): 498-505
7. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum CA, Schild U, Regez K, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B (2009) Effect of procalcitoninbased guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302(10):1059-1066
8. Schuetz P, Christ-Crain M, Müller B (2009) Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype? Swiss Med Wkly 139(23-24):318-326
9. Lee RW, Lindstrom ST (2007) A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology 12(5):754-758
10. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336(4):243-250
11. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543-551
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709-717
13. Calverley PM, Walker P (2003) Chronic obstructive pulmonary disease. Lancet 362(9389):1053-1061
14. Gonzales R, Sande MA (2000) Uncomplicated acute bronchitis. Ann Intern Med 133(12):981-991
15. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163(7):1730-1754
16. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ (2005) Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26(6):1138-1180 (Pubitemid 41829947)
17. Anthonisen NR, Manfreda J,Warren CP, Hershfield ES, Harding GK, Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106(2):196-204